High Risk CLL
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL (NCT05478512) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2023-07-21 |
Track High Risk CLL automatically
Every clearance here is in the API, with alerts when new ones post.